UBS raised the firm’s price target on Dillard’s (DDS) to $170 from $150 and keeps a Sell rating on the shares. Dillard’s Q1 comp sales decline and elevated inventories reinforce the firm’s view that near-term earnings should remain under pressure, the analyst tells investors in a research note. UBS forecasts a (17%) five-year EPS compound annual growth rate and expects continuous EPS declines.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DDS: